Tissue biomarkers in renal cell carcinoma: Issues and solutions

Renal cell carcinoma (RCC) is an aggressive malignancy that is associated with a high rate of metastasis. Although several promising therapeutic strategies are now available for the treatment of patients with metastatic kidney cancer, the prognosis of these patients remains poor. Research is ongoing to identify RCC‐specific biomarkers that can improve early diagnosis, surveillance of tumor progression, and prediction of patient prognosis. The identification of biomarkers that may predict response to specific therapies also will be useful in stratifying patients with RCC for treatment selection. Unfortunately, biomarker detection and measurement in kidney tumor tissues can be biased significantly by the lack of standardization in tissue sample acquisition, storage, and analysis. Consequently, the establishment of standardized operating procedures is necessary to maximize the accuracy of tissue‐based biomarker assays. Herein, the authors discuss current issues in tissue‐based translational research aimed at identifying clinically useful biomarkers for kidney cancer. Cancer 2009;115(10 suppl):2290‐7. © 2009 American Cancer Society.

[1]  B. Rini,et al.  Emerging drugs for renal cell carcinoma , 2010, Expert opinion on emerging drugs.

[2]  P. Humphrey,et al.  Percentage of high‐grade carcinoma as a prognostic indicator in patients with renal cell carcinoma , 2008, Cancer.

[3]  F. Waldman,et al.  Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions , 2008, Clinical Cancer Research.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  J. Patard,et al.  Prognostic factors and selection for clinical studies of patients with kidney cancer. , 2008, Critical reviews in oncology/hematology.

[6]  L. Qin,et al.  Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma: An Immunohistochemical Study Comparing 2 Antibodies , 2008, The American journal of surgical pathology.

[7]  David B Seligson,et al.  Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[8]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Clark,et al.  Recent advances in targeted therapy for renal cell carcinoma , 2007, Current opinion in urology.

[10]  B. Escudier.  Sorafinib in kidney cancer , 2007 .

[11]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[12]  M. Pacyna‐Gengelbach,et al.  Antigenicity testing by immunohistochemistry after tissue oxidation , 2007, Journal of Clinical Pathology.

[13]  Clive R. Taylor,et al.  Standardization of Immunohistochemistry for Formalin-fixed, Paraffin-embedded Tissue Sections Based on the Antigen-retrieval Technique: From Experiments to Hypothesis , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[14]  S. Signoretti,et al.  The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer , 2007, Clinical Cancer Research.

[15]  P. Choyke,et al.  Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics , 2007, Clinical Cancer Research.

[16]  M. Carini,et al.  Re: Anders Lidgren, Ylva Hedberg, Kjell Grankvist, Torgny Rasmuson, Anders Bergh and Börje Ljungberg. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006;50:1272-7. , 2007, European urology.

[17]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[18]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[19]  B. Escudier.  Sorafenib [corrected] in kidney cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  D. Rimm,et al.  Immunohistochemistry and quantitative analysis of protein expression. , 2009, Archives of pathology & laboratory medicine.

[21]  K. Grankvist,et al.  Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray , 2006 .

[22]  R. Walker,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment I , 2006, Histopathology.

[23]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[24]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[25]  A. Renshaw.  Review of Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist , 2006 .

[26]  F. Pontén,et al.  Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens , 2006, Laboratory Investigation.

[27]  D. Rimm,et al.  Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.

[28]  D. Demetrick,et al.  A novel method for freezing and storing research tissue bank specimens. , 2005, Human pathology.

[29]  Cheng Liu,et al.  Protein-embedding Technique: A Potential Approach to Standardization of Immunohistochemistry for Formalin-fixed, Paraffin-embedded Tissue Sections , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  K. A. DiVito,et al.  Tissue microarrays – automated analysis and future directions , 2005 .

[31]  C. Fenoglio-Preiser,et al.  Stability of Phosphoprotein as a Biological Marker of Tumor Signaling , 2005, Clinical Cancer Research.

[32]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[33]  K. Grankvist,et al.  The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  David A. Drubin,et al.  Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens , 2005, Breast Cancer Research and Treatment.

[35]  D. Rimm,et al.  Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.

[36]  F. Radvanyi,et al.  Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. , 2004, Analytical biochemistry.

[37]  A. Gown,et al.  Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. , 2004, American journal of clinical pathology.

[38]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  S. Jewell,et al.  Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids , 2022 .

[41]  Mahul B. Amin,et al.  Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases , 2002, The American journal of surgical pathology.

[42]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[43]  S. Schnitt,et al.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.

[44]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[45]  Clive R. Taylor,et al.  Review of Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist: , 1986 .

[46]  L. Sternberger,et al.  Immunoperoxidase technics in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute. , 1979, American journal of clinical pathology.